{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T16:06:40Z","timestamp":1784909200186,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jtha.2023.11.030","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T17:10:11Z","timestamp":1703265011000},"page":"896-904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeted ADAMTS-13 replacement therapy for thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"22","author":[{"given":"Jonathan J.","family":"Moroniti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Vrbensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2023.11.030_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2023.11.030_bib2","first-page":"536","article-title":"Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management","volume":"10","author":"Sukumar","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2023.11.030_bib3","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00005792-198111000-00003","article-title":"Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature","volume":"60","author":"Ridolfi","year":"1981","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jtha.2023.11.030_bib4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2023.11.030_bib5","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1537-2995.2006.00687.x","article-title":"Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"46","author":"Howard","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.jtha.2023.11.030_bib7","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S0049-3848(02)00153-6","article-title":"Practical guidelines for the clinical use of plasma","volume":"107","author":"Hellstern","year":"2002","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2023.11.030_bib8","series-title":"Enzyme Replacement Therapy. LiverTox: clinical and research information on drug-induced liver injury","year":"2012"},{"key":"10.1016\/j.jtha.2023.11.030_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.jtha.2023.11.030_bib10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jth.13341","article-title":"Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Kopic","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib11","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib12","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1161\/ATVBAHA.115.306014","article-title":"Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura","volume":"35","author":"Tersteeg","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.11.030_bib13","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2023.11.030_bib14","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A\u00a0new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib15","article-title":"Phase 3 prospective, randomized, controlled, open-label, multicenter, crossover study of recombinant ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura [abstract]","author":"Scully","year":"2023","journal-title":"ISTH Congress"},{"key":"10.1016\/j.jtha.2023.11.030_bib16","article-title":"Pharmacokinetic characteristics of ADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura: interim results from a phase 3 randomized, controlled, open-label, crossover study [abstract]","author":"Cataland","year":"2023","journal-title":"ISTH Congress"},{"key":"10.1016\/j.jtha.2023.11.030_bib17","article-title":"Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: interim analysis from phase 3b continuation study [abstract]","author":"Coppo","year":"2023","journal-title":"ISTH Congress"},{"key":"10.1016\/j.jtha.2023.11.030_bib18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib19","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1111\/jth.13137","article-title":"Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13","volume":"13","author":"Plaimauer","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000968132.86513.06","article-title":"S305: phase 2 randomized, placebo-controlled, double-blind, multicenter study of recombinant ADAMTS13 in patients with immune-mediated thrombotic thrombocytopenic purpura","volume":"7","author":"Scully","year":"2023","journal-title":"HemaSphere"},{"key":"10.1016\/j.jtha.2023.11.030_bib21","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1182\/blood-2014-07-587139","article-title":"Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models","volume":"125","author":"Pickens","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib22","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/ATVBAHA.118.311407","article-title":"Transfusion of platelets loaded with recombinant ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpura","volume":"38","author":"Abdelgawwad","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.11.030_bib23","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1038\/s41598-018-26298-4","article-title":"mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice","volume":"8","author":"Liu-Chen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2023.11.030_bib24","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2013-02-486779","article-title":"AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura","volume":"121","author":"Jin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/ATVBAHA.116.308680","article-title":"Long-term prevention of congenital thrombotic thrombocytopenic purpura in ADAMTS13 knockout mice by Sleeping Beauty transposon-mediated gene therapy","volume":"37","author":"Verhenne","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2023.11.030_bib26","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib27","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1182\/blood.2020007972","article-title":"N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP","volume":"137","author":"Ercig","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib28","article-title":"GC1126A, a novel ADAMTS13 mutein that evades autoantibody as a superior therapy for acquired thrombotic thrombocytopenic purpura (aTTP) [abstract]","author":"Nam","year":"2023","journal-title":"ISTH Congress"},{"key":"10.1016\/j.jtha.2023.11.030_bib29","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.addr.2010.06.007","article-title":"Platelets as delivery systems for disease treatments","volume":"62","author":"Shi","year":"2010","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtha.2023.11.030_bib30","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"Furlan","year":"1999","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2023.11.030_bib32","first-page":"2157","article-title":"Ectopic platelet-delivered factor (F) VIII for the treatment of hemophilia A: plasma and platelet FVIII, is it all the same?","author":"Greene","year":"2011","journal-title":"J\u00a0Genet Syndr Gene Ther"},{"key":"10.1016\/j.jtha.2023.11.030_bib33","first-page":"5722","article-title":"Enhancing therapeutic efficacy of in\u00a0vivo platelet-targeted gene therapy in hemophilia A mice","volume":"4","author":"Wang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2023.11.030_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.1981.03320170043028","article-title":"Hazard of platelet transfusion in thrombotic thrombocytopenic purpura","volume":"246","author":"Harkness","year":"1981","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2023.11.030_bib35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.jtha.2023.11.030_bib36","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1038\/s41591-022-02061-1","article-title":"The landscape of mRNA nanomedicine","volume":"28","author":"Huang","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2023.11.030_bib37","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1182\/blood-2002-05-1397","article-title":"Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)","volume":"100","author":"Plaimauer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2023.11.030_bib38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1160\/TH06-02-0100","article-title":"ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura","volume":"95","author":"Tsai","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jth.12494","article-title":"Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura","volume":"12","author":"Lotta","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2023.11.030_bib40","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3324\/haematol.2013.094151","article-title":"Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura","volume":"99","author":"Ferrari","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2023.11.030_bib41","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2023.11.030_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtha.2023.11.030_bib43","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jimd.12270","article-title":"A\u00a0primer to gene therapy: progress, prospects, and problems","volume":"44","author":"Zittersteijn","year":"2021","journal-title":"J\u00a0Inherit Metab Dis"},{"key":"10.1016\/j.jtha.2023.11.030_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtha.2023.11.030_bib45","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tig.2017.08.008","article-title":"Gene therapy with the Sleeping Beauty transposon system","volume":"33","author":"Kebriaei","year":"2017","journal-title":"Trends Genet"},{"key":"10.1016\/j.jtha.2023.11.030_bib46","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jtha.2022.12.018","article-title":"Toward gene therapy for congenital thrombotic thrombocytopenic purpura","volume":"21","author":"Dekimpe","year":"2023","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623009182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783623009182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:08:08Z","timestamp":1744452488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623009182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1538783623009182"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2023.11.030","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted ADAMTS-13 replacement therapy for thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2023.11.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}